Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Debbie O'Reilly"'
Autor:
Debbie O'Reilly, Tim Downing, Sana Kouba, Marie Potier-Cartereau, Declan J. McKenna, Christophe Vandier, Paul Buchanan
Publikováno v:
Data in Brief, Vol 42, Iss , Pp 108143- (2022)
The data generated here in relates to the research article “CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer”. A model of prostate cancer (PCa) progression to castration resistance was employed
Externí odkaz:
https://doaj.org/article/c960f9324a014268ae280a04722ca477
Publikováno v:
Cancer Research. 83:P6-12
Introduction: NER is a pan-HER tyrosine kinase inhibitor (TKI) approved for the treatment of HER2+ BC in the adjuvant setting following trastuzumab and in combination with capecitabine for advanced disease. Resistance to small molecule TKIs like NER
Autor:
Debbie O'Reilly, Paul J. Buchanan
Publikováno v:
Bioelectricity. 4:81-91
Autor:
Debbie O'Reilly, Nicola Gaynor, Neil Conlon, Irmina Diala, Lisa D Eli, John Crown, Denis M Collins
Publikováno v:
Cancer Research. 82:P2-13
Introduction: Treatment strategies for HER2+ breast cancer (BC) involves first line treatment with the monoclonal antibody trastuzumab, however resistance to treatment can occur. The pan-HER tyrosine kinase inhibitor neratinib is an approved adjuvant
Autor:
Tim Downing, Christophe Vandier, Sana Kouba, Declan J. McKenna, Marie Potier-Cartereau, Debbie O'Reilly, Paul Buchanan
Publikováno v:
Cell Calcium. 103:102554
Androgen deprivation therapy (ADT) is the main treatment for advanced prostate cancer (PCa) but resistance results in progression to terminal castrate resistant PCa (CRPC), for which there is an unmet therapeutic need. Altered calcium channel functio
Autor:
Paul Buchanan, Debbie O'Reilly
Publikováno v:
Cell calcium. 81
Cancer stem cells (CSC's) have emerged as a key area of investigation due to associations with cancer development and treatment resistance, related to their ability to remain quiescent, self-renew and terminally differentiate. Targeting CSC's in addi
Publikováno v:
Steroids. 152:108497
Androgen deprivation therapy (ADT) is the main treatment to prolong survival in advance stage prostate cancer (PCa) but associated resistance leads to the development of terminal castrate resistant PCa (CRPC). Current research demonstrates that prost